Register for OBR daily

To find out more about a company click on the company name to see a brief profile.

OBR Finance Top 5 Winners

ONTY $3.01 0.5000 +19.92%
CBMG $35.64 4.5100 +14.49%
BLRX $2.02 0.1700 +9.19%
XBIT $20.59 1.5400 +8.08%
INO $8.83 0.5700 +6.90%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

OBR Finance Top 5 Losers

CALA $11.00 -1.0200 -8.49%
TKAI $10.95 -0.9100 -7.67%
CLSN $2.63 -0.1701 -6.08%
CVM $0.75 -0.0400 -5.06%
BDSI $8.10 -0.3900 -4.59%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

Archived News Headlines

We have been archiving all OBR daily news stories since March 2008. Use the box below to search our archives for specific articles and content.

Please note: we do not "host" news articles on our website. When a media source removes an article from their website the link becomes inactive, and you will only be able to see the date, title, first sentence and media source that published the article.

<< First | < Prev | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | Next > | Last >>

AbbVie to Present New Data from Studies of Five Oncology Pipeline Assets in Multiple Cancers at the 51st American Society of Clinical Oncology Annual Meeting

(MarketWatch) May 11, 2015 - Seventeen abstracts include data from: Phase 1 trials evaluating venetoclax in relapsed or refractory multiple myeloma; Phase 2 study evaluating the potential of veliparib in advanced NSCLC patients with history of smoking; Studies of ABT-414 in glioblastoma multiforme and solid tumors, duvelisib in treatment naive chronic lymphocytic leukemia and elotuzumab in multiple myeloma.
read article 

Pivotal Data for Roche Medicines in Lung and Blood Cancers to be Presented at ASCO

(Roche) May 11, 2015 - Roche today announced that data from 10 of its approved cancer medicines and 10 of its investigational medicines will be presented during the American Society of Clinical Oncology (ASCO) Annual Meeting from 29th May - 2nd June in Chicago, United States.
read corporate press release 

Study Finds Metabolic Link Between Bacterial ‘Biofilms’ and Colon Cancer

(TSRI) May 7, 2015 - A team led by scientists at The Scripps Research Institute (TSRI) and Johns Hopkins University School of Medicine has uncovered a big clue to how bacteria may promote some colon cancers.
read press release 

First-in-class Antibody Mixture Shows Clinical Activity Against Treatment-resistant, Advanced Colorectal Cancer

(AACR) May 11, 2015 - Sym004, a mixture of two anti-epidermal growth factor receptor (EGFR) antibodies, was found to be clinically active in patients with advanced colorectal cancer that had become resistant to prior anti-EGFR therapies, according to a study published in Cancer Discovery, a journal of the American Association for Cancer Research.
read press release 

Most Women are Unaware of New Guidelines for Pap Test Frequency, Penn Medicine Study Reveals

(Penn Medicine) May 8, 2015 - Women know that Pap tests are a useful screening test for cervical cancer, but according to a new study led by researchers at the Perelman School of Medicine at the University of Pennsylvania, most of those surveyed are unaware of the updated screening guidelines for the appropriate frequency of Pap tests in low-risk women.
read press release 

They Overcame Childhood Cancer, But Now Obesity?

(Health/HealthDay News) May 11, 2015 - Certain treatments may increase a childhood cancer survivor’s risk of obesity later in life, a new study says.
read article 

Study May Suggest New Strategies for Myelodysplastic Syndromes Treatment

(MD Anderson) May 11, 2015 - A study revealing fresh insight about chromosome “tails” called telomeres may provide scientists with a new way to look at developing treatments or even preventing a group of blood cell disorders known as myelodysplastic syndromes (MDS).
read press release 

Expanding Options for Follicular Lymphoma Patients in Relapse

(MedPage Today) May 8, 2015 - Though indolent in nature and generally responsive to treatment, follicular lymphoma (FL) remains an incurable disease, despite the fact that median overall survival exceeds 10 years. Nonetheless, most patients eventually relapse at some point in the clinical history of the disease.
read article (free registration required) 

Antibiotic-Chemo Combo Cuts Infection Risk in AML

(MedPage Today) May 10, 2015 - Children with acute myeloid leukemia (AML) had a significantly lower incidence of certain bacterial infections if they received fluoroquinolone prophylaxis after chemotherapy, a small retrospective study showed.
read article (free registration required) 

T-Cell Therapy Active in Kids with ALL

(MedPage Today) May 10, 2015 - Children with acute lymphoblastic leukemia (ALL) achieved complete and durable remissions when treated with targeted immunotherapy using modified T-cells, according to a study here.
read article (free registration required) 

Roche Receives FDA Approval for cobas® KRAS Mutation Test

(Yahoo! Finance) May 11, 2015 - Molecular PCR test identifies KRAS mutations to aid in determining therapy for metastatic colorectal cancer.
read article 

Personalized Cancer Therapy Boasts Success, and High Price

(Philadelphia Inquirer/Seattle Times) May 10, 2015 - Though molecularly targeted drugs are not yet available for most cancer patients, they account for the majority of the 45 new cancer drugs launched since 2010, a report by IMS Health found.
read article 

New Blood Tests, Liquid Biopsies, May Transform Cancer Care

(ABC News/Associated Press) May 11, 2015 - A new type of blood test in the U.S. is starting to transform cancer treatment, sparing some patients the surgical and needle biopsies long needed to guide their care.
read article 

On Medicare and Assessing the Value of Lung Cancer Screening

(New York Times/The New Old Age blog) May 8, 2015 - You smoked for years. Maybe you still do. Now that Medicare promises to begin covering lung cancer screening, should you sign up?
read article 

Survival Odds Improving for Ovarian Cancer

(WebMD/HealthDay News) May 7, 2015 - Women diagnosed with ovarian cancer, traditionally viewed as an aggressive killer, are much more likely to survive the disease than they were several decades ago, new research shows.
read article 

Hepatitis C Infections Soaring, Fueled by Prescription Painkiller Abuse

(USA Today) May 7, 2015 - Rates of hepatitis C are soaring, largely driven by an epidemic of prescription painkiller abuse, a new report shows.
read article 

FDA Staff Say Vertex CF Combo Works, Unclear How

(Reuters) May 8, 2015 - FDA staff reviewers questioned whether Vertex Pharmaceuticals Inc's experimental cystic fibrosis drug added any benefit over its already approved therapy, Kalydeco, in patients with the most common genetic mutation underlying the disease.
read article 

Low-Dose CT Misses Lesions in Metastatic Liver Disease

(Medscape Medical News) May 7, 2015 - Low-radiation imaging misses too many lesions in patients undergoing abdominal CT for liver metastases, so standard doses of radiation are needed in these patients, say researchers.
read article (free registration required) 

The FDA Is on a Quest to Rid DTC Drug Ads of Confounding Fine Print

(Forbes) May 7, 2015 - In February, the FDA proposed that pharma companies should no longer be required to run endless pages of fine print describing potential side effects of their drugs in direct-to-consumer (DTC) print ads.
read article 

Drugmaker Sues F.D.A. Over Right to Discuss Off-Label Uses

(New York Times) May 7, 2015 - Drugmakers have long argued they should have the right to talk to doctors about unapproved uses for their products, as long as they are being truthful.
read article 

Surefire Medical’s New Precision Infusion System for Embolization Procedures Receives CE Mark Approval

(Yahoo! Finance) May 8, 2015 - Surefire Medical, Inc. today announced that the company’s new Precision targeted delivery infusion system, for direct-to-tumor embolization procedures, has received the CE Mark from European regulators.
read article 

TGA Approves AKYNZEO(R) (netupitant/palonosetron) for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV)

(TheStreet) May 8, 2015 - Australian biopharmaceutical company Specialised Therapeutics Australia (STA) and Helsinn, a Swiss group focused on building quality cancer care, announce that the Therapeutic Goods Administration (TGA) has approved AKYNZEO® for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately and highly emetogenic cancer chemotherapy.
read article 

National Cancer Center of Japan and Takeda Partner to Discover Anti-Cancer Agents

(Takeda) May 8, 2015 - The National Cancer Center and Takeda Pharmaceutical Company Limited announced today that they have signed an agreement with the goal to discover and develop superior, innovative anti-cancer agents originated in Japan and deliver them to cancer patients and their families as quickly as possible.
read corporate press release 

M.D. Anderson Blockbuster Licensing Deal Gets a New Twist

(Houston Chronicle) May 7, 2015 - The M.D. Anderson Cancer Center doctor behind an experimental therapy the institution earlier this year licensed to two biotech partners for $100 million in stock has been named the new chief executive officer of one of them.
read article (paid subscription required) 

ProHealth Contracts With UW Health to Oversee Care at New Pewaukee Cancer Center

(Milwaukee Journal-Sentinel) May 7, 2015 - ProHealth Care will contract with UW Health to oversee the medical care at its new cancer center scheduled to open this year in Pewaukee.
read article